1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 10 at diagnosis
Sponsor: Other
Protocol IDs: CHLA-HEAD-START-III, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 21 at diagnosis
Sponsor: NCI, Other
Protocol IDs: CDR0000367486, SJCRH-SJMB03, NCT00085202
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Other
Protocol IDs: CNS 0201, NCT00179907
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 120
Sponsor: Other
Protocol IDs: R01 CA 89395-01, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-110, SUN08-01, NCT00704054
|
|
6.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
7.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: COG-ADVL0912, ADVL0912, NCT00939770
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: OHSU-5056, OHSU SOL-08131-L, NCT00983398
|
|
9.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 3 to 21
Sponsor: NCI, Other
Protocol IDs: MGH-99-271, NCT00105560
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: NYU 05-40 H12853, PBMTC ONC-032P, NCT00528437
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 3368, NCT00576537
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: 12555, NCT00589706
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Children
Sponsor: Other
Protocol IDs: 2005-12-009, NCT00798811
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 20 years
Sponsor: Other
Protocol IDs: CSET 2008/1378, NCT00918320
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 months and over
Sponsor: NCI
Protocol IDs: OHSU-1299, OHSU-ONC-98018-L, OHSU-4834, NCT00253721
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: PBTC-020, NCT00326664
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: NCI
Protocol IDs: CPMC-AAAA-4229, CPMC-14220, NCT00324844
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 4 to 16
Sponsor: NCI
Protocol IDs: NCI-07-C-0054, NCT00437047
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: PBTC-023, PBTC-023, NCT00503724
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 2007-0370, NCT00513162
|
|
25.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 21
Sponsor: NCI
Protocol IDs: PBTC-024, PBTC-024, NCI-09-C-0112, NCT00572182
|
